The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.
People with diabetes are 50% more likely to die of a heart attack, according to a large population study.
While the link between heart disease and diabetes has been well-known, researchers at the University of Leeds have pinned down the precise risk after evaluating records from 700,000 patients admitted to the hospital for a heart attack between January 2003 and June 2013.
Of this group, 121,000 had diabetes.
Researchers controlled for age, gender, and other differences—including the quality of medical care—and the difference of having diabetes emerged as a huge factor in whether a patient survived.
Among those who experienced a ST elevation myocardial infarction, or STEMI heart attack —in which the coronary artery is completely blocked—those with diabetes were 56% more likely to die from the episode.
Those with a non-STEMI attack, in which the coronary artery is partially blocked, were still 39% more likely to die if they had diabetes.
The importance of cardiovascular (CV) protection in diabetes care is paramount among regulators who monitor medications for diabetes and obesity. Since 2008, the FDA has required exhaustive, multi-year trials of new therapies to ensure they do not produce long-term CV harms.
Since last year, 2 therapies—empagliflozin and liraglutide—have been shown to produce come CV benefits without other apparent effects. The importance of preventing CV mortality in diabetes care was discussed by an expert panel convened by The American Journal of Managed Care this spring, and can be found here.
Results for liraglutide were presented at the recent 76th Scientific Sessions of the American Diabetes Association in New Orleans, Louisiana. The therapy was found to reduce CV death risk by 22%.
In the new study published this week, lead researcher Chris Gale, PhD, MSc, FRCP, consultant cardiologist and associate professor at the University of Leeds School of Medicine, said the results offer “robust evidence” that diabetes is a long-term contributing factor among those who suffer fatal heart attacks.
“Although these days people are more likely than ever to survive a heart attack, we need to place greater focus on the long-term effects of diabetes in heart attack survivors,” he said.
Gale said the next step would be to figure out why diabetes raises the risk of cardiac death so significantly.
Reference
doi:10.1136/jech-2016-207402
Alabas OA, Hall M, Dondo TB, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population based cohort study [published online June 15, 2016]. J Epidemiol Community Health. .
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen